Ionis Pharmaceuticals is poised to launch olezarsen, a groundbreaking treatment for familial chylomicronemia syndrome (FCS), a rare genetic disorder affecting 1-2 per million people globally. As reported by PRNewswire, the FDA has accepted olezarsen's New Drug Application for Priority Review, potentially making it the first approved therapy for FCS in the United States.